New antibody treatment for Non-Hodgkin Lymphoma and a type of skin lymphoma
Official title: Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).
Funded at Boston Immune Technologies and Therapeutics, INC. · NIH-11131238 · Data updated 2026-11-12
This project is testing a new antibody treatment, called BITR2101, for people with certain types of cancer, including Non-Hodgkin Lymphoma and Cutaneous T Cell Lymphoma.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Immune Technologies and Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Winchester, United States) |
| Project start | September 1, 2021 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $2,409,283 |
| NIH project number | 5R44CA265510-05 |
| Project ID | NIH-11131238 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with Non-Hodgkin Lymphoma, especially those with Cutaneous T Cell Lymphoma, might be ideal candidates for future studies related to this treatment.
✕Less likely to help
Patients whose cancer does not express the TNFR2 protein or who have other cancer types not targeted by this specific mechanism may not receive benefit.
What this research studies
This research focuses on developing a new antibody, BITR2101, designed to fight cancer by targeting a specific protein called TNFR2. This protein is found on cancer cells and also on cells in the surrounding tissue that help the cancer grow and resist treatment. By blocking TNFR2, this antibody aims to stop cancer growth and make other treatments more effective. Researchers hope this approach will be useful for several types of cancer, either alone or combined with other therapies.
Why it matters
Potential benefit: If successful, this new antibody could offer a more effective way to treat Non-Hodgkin Lymphoma and Cutaneous T Cell Lymphoma by directly attacking cancer cells and their protective environment.
How similar studies have gone: This antibody, BITR2101, is described as the first and only one of its kind to dominantly shut down TNFR2 signaling, suggesting a novel approach.
Where this research is happening
-
Boston Immune Technologies and Therapeutics, INC.
Winchester, United States Active
Researchers
- Principal investigator: Brooks, David G — Boston Immune Technologies and Therapeutics, INC.
- Study coordinator: Brooks, David G
Related research
Other NIH-funded projects on the same topics.
-
New treatment targeting cancer cells and their supportive environment in Non-Hodgkin Lymphoma.
This study is testing a new treatment called BITR2101 that targets a specific part of cancer cells to help stop the growth of Non-Hodgkin Lymphoma, especially for those with Cutaneous T Cell Lymphoma, and it may be used on its own or with other therapies to improve patient outcomes.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
IL-15 and skin-homing CTCL: a targeted approach to curb skin lesions
This grant studies how the inflammatory signal IL-15 drives CTCL T cells to settle in the skin and how blocking this pathway might help patients with this skin-limited leukemia.
-
Staphylococcus aureus and CTCL: How skin bacteria may drive a blood cancer
A doctor-scientist team is studying how certain strains of Staphylococcus aureus on the skin might influence the development and progression of cutaneous T-cell lymphoma (CTCL) in patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.